Jane Street
ALXN

Jane Street’s Alexion Pharmaceuticals ALXN Stock Holding History

Jane Street’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-33,400
Closed -$6.14M – 11268
2021
Q2 		$6.14M Sell
33,400
-20,000
-37% -$3.43M ﹤0.01% 2336
2021
Q1 		$8.16M Sell
53,400
-177,100
-77% -$27.4M ﹤0.01% 1756
2020
Q4 		$36M Sell
230,500
-22,300
-9% -$2.87M 0.02% 561
2020
Q3 		$28.9M Buy
252,800
+6,400
+3% +$690K 0.02% 600
2020
Q2 		$27.7M Buy
246,400
+231,700
+1,576% +$24.6M 0.02% 599
2020
Q1 		$1.32M Sell
14,700
-55,200
-79% -$5.42M ﹤0.01% 2480
2019
Q4 		$7.56M Sell
69,900
-300
-0.4% -$32.1K 0.01% 798
2019
Q3 		$6.88M Buy
70,200
+46,500
+196% +$5.24M 0.01% 784
2019
Q2 		$3.1M Buy
23,700
+8,600
+57% +$1.11M 0.01% 1445
2019
Q1 		$2.04M Sell
15,100
-101,800
-87% -$12.7M ﹤0.01% 2006
2018
Q4 		$11.4M Buy
116,900
+106,200
+993% +$12.6M 0.02% 512
2018
Q3 		$1.49M Sell
10,700
-39,000
-78% -$4.89M ﹤0.01% 2248
2018
Q2 		$6.17M Sell
49,700
-70,500
-59% -$8.24M 0.01% 884
2018
Q1 		$13.4M Buy
120,200
+83,500
+228% +$9.98M 0.03% 429
2017
Q4 		$4.39M Sell
36,700
-1,200
-3% -$146K 0.01% 962
2017
Q3 		$5.32M Sell
37,900
-24,300
-39% -$3.3M 0.02% 837
2017
Q2 		$7.57M Buy
62,200
+38,500
+162% +$4.48M 0.03% 577
2017
Q1 		$2.87M Sell
23,700
-80,700
-77% -$10.4M 0.01% 1065
2016
Q4 		$12.8M Buy
104,400
+95,300
+1,047% +$11.7M 0.06% 279
2016
Q3 		$1.11M Sell
9,100
-7,000
-43% -$901K 0.01% 1822
2016
Q2 		$1.88M Buy
16,100
+9,800
+156% +$1.39M 0.01% 1331
2016
Q1 		$877K Buy
+6,300
New +$925K ﹤0.01% 1973
2015
Q4 		– Sell
-4,000
Closed -$626K – 4624
2015
Q3 		$626K Buy
4,000
+1,900
+90% +$347K ﹤0.01% 2077
2015
Q2 		$380K Buy
+2,100
New +$362K ﹤0.01% 2571

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Jane Street's ALXN Position: Q3 2021 in Review

Jane Street sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 46,663 shares — an estimated $8.57M sold.

Jane Street first reported a position in ALXN in Q2 2013 and held it in 29 quarters. The position peaked at $24.5M in Q3 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jane Street reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jane Street sold 46,663 Alexion Pharmaceuticals shares in Q3 2021, an estimated $8.57M.
  • Jane Street first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 29 quarters.
  • Jane Street's Alexion Pharmaceuticals position peaked at $24.5M in Q3 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Jane Street's 13F filing for Q3 2021, filed 16 Nov 2021.